泰坦制药
TTNP

From March 31, 2025 to June 30, 2025 Issuance of preferred stock Issuance of common stock upon conversion of preferred stock

From December 31, 2023 to March 31, 2024 Fractional shares issued due to reverse stock split Issuance of common stock upon conversion of note payable

Titan Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock.

From December 31, 2021 to December 31, 2022 Issuance of common stock, net Issuance of common stock upon exercise of warrants Amortization of restricted stock

From December 31, 2021 to March 23, 2022 Issuance of common stock, net Issuance of common stock upon exercises of warrants

1.Securities offered by in this offering 1,100,000 shares 2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 9,914,158 shares outstanding as of February 1, 2022

1.Common stock offered by the company in this offering 2,725,000 shares. 2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 7,139,068 shares outstanding as of January 14, 2021.

From December 31, 2019 to December 31, 2020 Issuance of common stock, net Issuance of common stock upon exercise of warrants, net Reverse stock split adjustments

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, November 30, 2020. Immediately after the reverse split becomes effective, there will be approximately 6.6 million shares of common stock issued and outstanding.

1.Units offered 80,000,000 units. Each unit consists of one share of common stock. 2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 116,763,180 shares outstanding as of October 28, 2020.

From June 30, 2020 to September 30, 2020 Issuance of common stock, net Issuance of common stock upon exercises of warrants, net

1.Common stock offered by the company in this offering 19,440,000 shares. 2.The number of shares of common stock that will be outstanding immediately after this offering as shown above is based on 97,323,180 shares outstanding as of September 23, 2020.

From March 31, 2020 to June 30, 2020 Issuance of common stock upon exercises of warrants, net

From December 31, 2019 to March 25, 2020 Issuance of common stock, net Issuance of common stock upon exercises of warrants

From December 31, 2018 to November 18, 2019 Issuance of common stock, net Issuance of common stock upon exercise of warrants, net Issuance of common stock upon conversion of convertible debt

From June 30, 2019 to September 30, 2019 Issuance of common stock upon exercises of warrants, net Issuance of common stock, net

from March 31, 2019 to June 30, 2019 Issuance of common stock upon exercises of warrants, net Issuance of common stock upon conversion of convertible loan Issuance of common stock in at-the-market offerings, net

from December 31, 2018 to March 31, 2019 Issuance of common stock upon exercises of warrants, net

On January 23, 2019, Titan Pharmaceuticals, Inc. (the “Company” or “Titan”) filed a Certificate of Amendment to its Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware for the purpose of effecting a reverse stock split (the “Reverse Split”) of the outstanding shares of the Company’s common stock at a ratio of one (1) share for every six (6) shares outstanding, so that every six (6) outstanding shares of common stock before the Reverse Split represents one (1) share of common stock after the Reverse Split. The Reverse Split, which was approved by Titan’s stockholders at the special meeting of stockholders held on January 23, 2019 (the “Special Meeting”), will be effective at 5:00 p.m. eastern time on January 24, 2019. Immediately prior to the Reverse Split, there were 77,974,644 shares of common stock outstanding. After the Reverse Split, there will be approximately 12,995,774 shares outstanding.

from December 31, 2016 to December 31, 2017 Issuance of common stock, net

From December 31, 2015 to December 31, 2016 Issuance of common stock upon exercise of warrants, net Issuance of common stock upon exercise of options, net

From December 31, 2014 to November 18, 2015 Issuance of common stock upon vesting of restricted stock awards, net On September 29, 2015, pursuant to prior shareholder authorization, our Board effected the Reverse Split of the outstanding shares of our common stock at a ratio of one (1) share for every five and one-half (5.5) shares outstanding, so that every five and one-half (5.5) outstanding shares of common stock before the Reverse Split represents one (1) share of common stock after the Reverse Split.

On September 29, 2015, pursuant to prior shareholder authorization, our Board effected the Reverse Split of the outstanding shares of our common stock at a ratio of one (1) share for every five and one-half (5.5) shares outstanding, so that every five and one-half (5.5) outstanding shares of common stock before the Reverse Split represents one (1) share of common stock after the Reverse Split.

from December 31, 2013 to December 31, 2014 Issuance of common stock, net of issuance costs Issuance of common stock upon vesting of restricted stock awards, net